Sherron Jackson to Hydroxyurea
This is a "connection" page, showing publications Sherron Jackson has written about Hydroxyurea.
Connection Strength
0.179
-
Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016 Feb 13; 387(10019):661-670.
Score: 0.126
-
Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood. 2014 Aug 07; 124(6):891-8.
Score: 0.028
-
Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. Am J Hematol. 2012 Apr; 87(4):428-30.
Score: 0.024